These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 10841972)

  • 1. Molecular basis of antibiotic resistance and beta-lactamase inhibition by mechanism-based inactivators: perspectives and future directions.
    Therrien C; Levesque RC
    FEMS Microbiol Rev; 2000 Jul; 24(3):251-62. PubMed ID: 10841972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The discovery and development of modified penicillin- and cephalosporin-derived beta-lactamase inhibitors.
    Buynak JD
    Curr Med Chem; 2004 Jul; 11(14):1951-64. PubMed ID: 15279575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-lactamases and beta-lactamase inhibitors.
    Williams JD
    Int J Antimicrob Agents; 1999 Aug; 12 Suppl 1():S3-7; discussion S26-7. PubMed ID: 10526867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination beta-lactam and beta-lactamase-inhibitor products: antimicrobial activity and efficiency of enzyme inhibition.
    Rotschafer JC; Ostergaard BE
    Am J Health Syst Pharm; 1995 Mar; 52(6 Suppl 2):S15-22. PubMed ID: 7606585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SHV-type beta-lactamases.
    Tzouvelekis LS; Bonomo RA
    Curr Pharm Des; 1999 Nov; 5(11):847-64. PubMed ID: 10539992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tackling the Antibiotic Resistance Caused by Class A
    Eiamphungporn W; Schaduangrat N; Malik AA; Nantasenamat C
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30061509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three decades of beta-lactamase inhibitors.
    Drawz SM; Bonomo RA
    Clin Microbiol Rev; 2010 Jan; 23(1):160-201. PubMed ID: 20065329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Energetic, structural, and antimicrobial analyses of beta-lactam side chain recognition by beta-lactamases.
    Caselli E; Powers RA; Blasczcak LC; Wu CY; Prati F; Shoichet BK
    Chem Biol; 2001 Jan; 8(1):17-31. PubMed ID: 11182316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitor-resistant TEM beta-lactamases: phenotypic, genetic and biochemical characteristics.
    Chaïbi EB; Sirot D; Paul G; Labia R
    J Antimicrob Chemother; 1999 Apr; 43(4):447-58. PubMed ID: 10350372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-lactamase-mediated resistance and opportunities for its control.
    Livermore DM
    J Antimicrob Chemother; 1998 Jun; 41 Suppl D():25-41. PubMed ID: 9688449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IRT and CMT beta-lactamases and inhibitor resistance.
    Cantón R; Morosini MI; de la Maza OM; de la Pedrosa EG
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():53-62. PubMed ID: 18154528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular analysis of beta-lactamase structure and function.
    Majiduddin FK; Materon IC; Palzkill TG
    Int J Med Microbiol; 2002 Jul; 292(2):127-37. PubMed ID: 12195735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on β-lactamase inhibitor discovery and development.
    Docquier JD; Mangani S
    Drug Resist Updat; 2018 Jan; 36():13-29. PubMed ID: 29499835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the development of β-lactamase inhibitors.
    Jalde SS; Choi HK
    J Microbiol; 2020 Aug; 58(8):633-647. PubMed ID: 32720096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in the chemistry of beta-lactam compounds as selected active-site serine beta-lactamase inhibitors.
    Mascaretti OA; Danelon GO; Laborde M; Mata EG; Setti EL
    Curr Pharm Des; 1999 Nov; 5(11):939-53. PubMed ID: 10539998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-lactamase inhibitors: the story so far.
    Pérez-Llarena FJ; Bou G
    Curr Med Chem; 2009; 16(28):3740-65. PubMed ID: 19747143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress toward inhibitors of metallo-β-lactamases.
    McGeary RP; Tan DT; Schenk G
    Future Med Chem; 2017 May; 9(7):673-691. PubMed ID: 28504895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment options for extended-spectrum beta-lactamase-producers.
    Essack SY
    FEMS Microbiol Lett; 2000 Sep; 190(2):181-4. PubMed ID: 11034276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-spectrum and inhibitor-resistant TEM-type beta-lactamases: mutations, specificity, and three-dimensional structure.
    Knox JR
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2593-601. PubMed ID: 8592985
    [No Abstract]   [Full Text] [Related]  

  • 20. Oxacillin-hydrolyzing beta-lactamase involved in resistance to imipenem in Acinetobacter baumannii.
    Hornstein M; Sautjeau-Rostoker C; Péduzzi J; Vessières A; Hong LT; Barthélémy M; Scavizzi M; Labia R
    FEMS Microbiol Lett; 1997 Aug; 153(2):333-9. PubMed ID: 9271860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.